15th week of 2016 patent applcation highlights part 6 |
Patent application number | Title | Published |
20160101021 | LIQUID-TRANSFER ADAPTER BEVELED SPIKE - A liquid-transfer adapter operatively interposable between an injector and a vial is provided. The adapter has an injector engaging portion configured for fluidly coupling to an injector and a vial coupling. The vial coupling includes a spike that has a spike axis and a tip portion configured for piercing a septum of a vial. The tip portion includes a plurality of facets that meet each other at one or more edges and at least one of the one or more edges is sloped with respect to the spike axis. The spike defines a channel extending therethrough in fluid communication with the injector engaging portion. A channel opening is defined in at least one of the facets and disposed without interrupting the edges. | 2016-04-14 |
20160101022 | PROCESS FOR THE PRODUCTION OF AN ABUSE-PROOFED SOLID DOSAGE FORM - The present invention relates to a process for the production of an abuse-proofed solid dosage form containing at least one active ingredient with potential for abuse and a binder with a breaking strength of ≧500 N, by exposing a mixture comprising the active ingredient and the binder to ultrasound and force. | 2016-04-14 |
20160101023 | Quick-Access Bottle Top For A Baby Bottle - A bottle top for use with a baby bottle includes a ring bounding a mouth of the bottle top and being severed latitudinally between upper and lower portions. The upper portion has first and second lower contact faces. The lower portion has opposing first and second upper contact faces. The top includes a nipple coupled to the upper portion which moves between an open position, in which the nipple is away from the mouth and provides access to the mouth, and a closed position, in which the first upper and lower contact faces form a sealing engagement, the second upper and lower contact faces form another sealing engagement, and the nipple is in fluid communication with the mouth. | 2016-04-14 |
20160101024 | Quick-Access Bottle Top For A Baby Bottle - A bottle top for use with a baby bottle includes a ring bounding a mouth of the bottle top and being severed latitudinally between upper and lower portions. The upper portion has first and second lower contact faces. The lower portion has opposing first and second upper contact faces. The top includes a nipple coupled to the upper portion which moves between an open position, in which the nipple is away from the mouth and provides access to the mouth, and a closed position, in which the first upper and lower contact faces form a sealing engagement, the second upper and lower contact faces form another sealing engagement, and the nipple is in fluid communication with the mouth. | 2016-04-14 |
20160101025 | Nipple-shaped pacifier kit - A nipple-shaped pacifier kit provides hypoallergenic molding powder, liquid silicone, a mixing bowl, a mixing tool, pacifier rings, and paper discs, each providing a slit for the insertion of the pacifier ring. The kit enables the adult user to create one or more pacifiers shaped like the human nipple. | 2016-04-14 |
20160101026 | Apertured Fibrous Structures and Methods for Making Same - Apertured fibrous structures and more particularly apertured fibrous structures containing one or more fibrous elements, for example filaments, containing one or more fibrous element-forming materials and one or more active agents that are releasable from the fibrous element when exposed to conditions of intended use, and methods for making same. | 2016-04-14 |
20160101027 | CLEANSING COMPOSITION WITH HIGH FATTY ACID CONTENT - A cosmetic cleansing composition includes a) 0.1 to 30 wt. %, based on the total weight of the cleansing composition, of a surfactant selected from the group of anionic, non-ionic, and/or zwitterionic surfactants and mixtures thereof, b) at least one partially and/or non-neutralized, unbranched, saturated and/or unsaturated carboxylic acid with a chain length of 14 to 30 carbon atoms, and c) at least one non-ionic polymer of the formula (I) as set forth herein, where R represents a hydrogen atom or a methyl group and n represents a whole number value from 1,360 to 99,000. The cleansing composition has a mousse-like texture and excellent cleansing and care properties. | 2016-04-14 |
20160101028 | CLEANING COMPOSITION HAVING IMPROVED SOIL REMOVAL - Cleaning compositions including a non-ionic surfactant and a glycol ether are disclosed. These cleaning compositions are useful as liquid cleaners or de-greasers for animate surfaces, such as skin. The cleaning compositions provide improved cleaning and removal of soils without the use of certain VOCs. | 2016-04-14 |
20160101029 | Systems and Methods for Skin Rejuvenation - Systems and methods for skin rejuvenation are disclosed herein. In an embodiment, a skin rejuvenation system includes a unit dose of a booster product that includes active ingredients of ferulic acid and phloretin; a unit dose of at least one exfoliating product that includes active ingredients of ferulic acid and phloretin in combination with fruit acids or alpha hydroxyacids; and a unit dose of a nano-additive product for enhancing penetration of the active ingredients. A method for skin rejuvenation includes applying topically, to a skin surface to be treated, a booster product including active ingredients of ferulic acid and phloretin; applying topically, to the skin surface, at least one exfoliating product including active ingredients of ferulic acid and phloretin in combination with one of fruit acids or alpha hydroxyacids; and applying topically, to the skin surface, a nano-additive product for enhancing penetration of the active ingredients. | 2016-04-14 |
20160101030 | COSMETIC COMPOSITION FOR PREVENTING SKIN AGING - Provided is a composition including, as an active ingredient, at least one selected from the group consisting of amines, amides and polyols. The cosmetic composition has an effect of preventing aging and may be applied in various industrial fields, including cosmetics. | 2016-04-14 |
20160101031 | Methods of Regulating Skin Health and Appearance with a Combination of Flavonoid and Vitamin B3 - The disclosure relates to topical compositions comprising a flavonoid compound and a vitamin B | 2016-04-14 |
20160101032 | PEPTIDE WITH ANTI-AGING EFFECT AND USE THEREOF - An object of the present invention to discover a short peptide having an anti-aging effect and to provide a novel anti-aging agent comprising the peptide as an active ingredient. The inventors have discovered that a peptide consisting of an amino acid sequence ELKLIFLHRLKRLRKRLKRK (SEQ ID NO: 1) or a partial sequence thereof and having one or more effects selected from the group consisting of promoting fibroblast growth, promoting hyaluronic acid production and contracting a collagen gel, or a derivative or salt of the peptide is useful as an active ingredient of an anti-aging agent. | 2016-04-14 |
20160101033 | Oil-Controlling Cosmetic Powder - A powder-based cosmetic composition for application to skin is provided. The composition contains (a) one or more cosmetically acceptable particulates which are naturally hydrophobic or coated with a hydrophobic material; (b) at least one binder for the particulates of the powder-based cosmetic composition; and (c) a film-forming, oil-absorbing polymer having an affinity for sebum secreted from skin. | 2016-04-14 |
20160101034 | ENZYMATIC SYSTEM-CONTAINING COSMETIC COMPOSITIONS - Cosmetic or pharmaceutical compositions are disclosed herein for application to skin, hair and/or a nail of a subject, as well as methods utilizing same for administering hydrogen peroxide to skin, hair and/or a nail, and kits for applying same. The compositions comprise a hydrogen peroxide-producing enzyme, and a substrate of the hydrogen peroxide-producing enzyme. Further disclosed herein are cosmetic compositions and kits for lightening skin and/or hair, which further comprise a lignin peroxidase, as well as cosmetic methods utilizing same. | 2016-04-14 |
20160101035 | ORAL AND DENTAL HYGIENE AND CLEANING AGENTS FOR REDUCING RE-STAINING OF TEETH - The invention relates to oral and dental hygiene and cleaning agents for reducing restaining of teeth. | 2016-04-14 |
20160101036 | SKIN CLEANSING COMPOSITION - Provided is a skin cleansing composition comprising the following components (A), (B), (C), (D), and (E): (A) 0.1 to 25 mass % of an ether oil which is in a liquid state at 25° C., (B) 0.003 to 1 mass % of a water-soluble polymer comprising acrylic acid or methacrylic acid as a constitutional unit, (C) 1 to 30 mass % of a hydrocarbon oil having a viscosity of 15 mPa·s or lower at 30° C., (D) 60 to 95 mass % of water, and (E) 0.49 mass % or less of a nonionic surfactant having an HLB of larger than 9, wherein the mass ratio of the component (B) to the component (A), (B)/(A) is from 0.0001 to 0.1, and the mass ratio between the component (A) and the component (C), (A)/((A)+(C)) is from 0.05 to 0.9. | 2016-04-14 |
20160101037 | LATEX NAIL COMPOSITIONS HAVING LOW AMOUNTS OF PHOTO-INITIATOR - Provided are nail compositions comprising at least one photo-curable polymer dispersed in water (latex), at least one acrylic non-photo-curable polymer dispersed in water (latex), at least one photo-initiator, optionally at least one plasticizer, optionally a colorant, and water. Also provided are nail composition systems and kits comprising the nail compositions of the invention together with a base coat composition and/or a top coat composition. | 2016-04-14 |
20160101038 | LATEX NAIL COMPOSITIONS HAVING LOW AMOUNTS OF PHOTO-INITIATOR - A nail compositions comprising at least one photo-curable polymer dispersed in water (latex), at least one non-photo-curable polymer dispersed in water (latex), at least one photo-initiator, optionally at least one plasticizer, optionally a colorant, and water are provided. Also provided are nail composition systems and kits comprising the nail compositions of the invention together with a base coat composition and/or a top coat composition. | 2016-04-14 |
20160101039 | LATEX NAIL COMPOSITIONS HAVING LOW AMOUNTS OF PHOTO-INITIATOR - A nail compositions comprising at least one photo-curable polymer dispersed in water (latex), at least one polyurethane non-photo-curable polymer dispersed in water (latex), at least one photo-initiator, optionally at least one plasticizer, optionally a colorant, and water are provided. Also provided are nail composition systems and kits comprising the nail compositions of the invention together with a base coat composition and/or a top coat composition. | 2016-04-14 |
20160101040 | COSMETIC COMPOSITION COMPRISING NONIONIC ASSOCIATIVE POLYMERS AND CARBOXYLATE ANIONIC SURFACTANTS, AND COSMETIC TREATMENT PROCESS - The present invention relates to a cosmetic composition, especially a hair composition, comprising: —one or more associative nonionic polymers especially of polyurethane polyether type in an amount ranging from 2% to 60% by weight relative to the total weight of the composition, and —one or more carboxylate anionic surfactants. The invention also relates to a cosmetic treatment process using the said composition, especially a hair treatment process in particular for cleansing the hair and/or the scalp. | 2016-04-14 |
20160101041 | COSMETIC COMPOSITION COMPRISING NONIONIC ASSOCIATIVE POLYMERS AND AMPHOTERIC SURFACTANTS, AND COSMETIC TREATMENT PROCESS - The present invention relates to a cosmetic composition, especially a hair composition, comprising: —one or more associative nonionic polymers especially of polyurethane polyether type in an amount ranging from 2.5% to 60% by weight relative to the total weight of the composition, and —one or more amphoteric surfactants. The invention also relates to a cosmetic treatment process using the said composition, especially a hair treatment process in particular for cleansing the hair and/or the scalp. | 2016-04-14 |
20160101042 | COMPOSITION COMPRISING AN EXTRACT OF HERBAL MEDICINE PROCESSED BY AN ORIENTAL HERBAL MEDICINE PROCESSING - The present specification relates to a composition comprising processed ginseng extract and processed green tea extract. Such a composition results in having a synergistic effect due to mixing of each processed extract, and is thus capable of promoting the production of procollagen and inhibiting the expression of collagenase. In addition, the composition of the present specification promotes the expression of filaggrin and is thus capable of strengthening a skin barrier function and inducing the differentiation of skin keratinocytes. Therefore, the composition of the present specification is capable of improving the general condition of skin, and can be effectively used as an external preparation for skin for preventing or improving xeroderma, atopic dermatitis, contact dermatitis, psoriasis, or the like that is caused by the imperfection of epidermal differentiation. | 2016-04-14 |
20160101043 | TRANSSCLERAL DRUG DELIVERY - Magnetic drug-loaded polymeric particles are used in a transscleral drug delivery method. In the synthesis process of the aforementioned magnetic drug-loaded polymeric particles, therapeutic agents, along with a magnetic agent are encapsulated in a polymer. The aforementioned magnetic drug-loaded particles can be placed near the outer surface of the sclera, and then a magnetic field can be applied in front of the eye to pull these magnetic drug-loaded particles to the outer surface of the sclera, where these particles adhere to the outer surface of the sclera and thus, the orbital clearance of the particles is eliminated or reduced. | 2016-04-14 |
20160101044 | LONG-LASTING INJECTABLE DRUG RELEASING GEL COMPOSITION AND METHOD OF MANUFACTURING THE SAME - A gel composition and method of manufacturing the same is discussed. The gel composition includes a plurality of chitosan spheres, an alkaline chitosan stabilizing agent, a chitosan decomposition enzyme and a drug. The chitosan spheres are formed by chitosan self-assembly. The alkaline chitosan stabilizing agent connects the chitosan spheres to form a gel body. The chitosan decomposition enzyme scatters in the gel body and decomposes the gel composition at a temperature of 20 to 40 degree Celsius. The drug scatters in the gel body. | 2016-04-14 |
20160101045 | NON-INVASIVE REFRACTIVE TREATMENT USING NANOPARTICLES - Embodiments of this invention generally relate to systems and methods for optical treatment and more particularly to non-invasive refractive treatment method based on sub wavelength particle implantation. In an embodiment, a method for optical treatment identifies an optical aberration of an eye, determines a dopant delivery device configuration in response to the optical aberration of the eye, wherein the determined dopant delivery device is configured to impose a desired correction to the eye to mitigate the identified optical aberration of the eye by applying a doping pattern to the eye so as to locally change a refractive index of the eye. | 2016-04-14 |
20160101046 | POSTERIOR SEGMENT DRUG DELIVERY - A therapeutic device to release a therapeutic agent comprises a porous structure coupled to a container comprising a reservoir. The reservoir comprises a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in the patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. A plurality of interconnecting channels can extend from the first side to the second side so as to connect a first a plurality of openings on the first side with a second plurality of openings on the second side. | 2016-04-14 |
20160101047 | ADULT AND NEONATAL STEM CELL THERAPY TO TREAT DIABETES THROUGH THE REPAIR OF THE GASTROINTESTINAL TRACT - The anatomic and functional arrangement of the gastrointestinal tract suggests an important function of this organ is its ability to regulate the trafficking of metabolites as well as control the equilibrium between tolerance and immunity through gut-associated lymphoid tissue, the neuroendocrine network, and the intestinal epithelial barrier. Combining nucleated cells from various tissues and introducing them directly into the small intestine will have a positive effect on diabetes. | 2016-04-14 |
20160101048 | +L-CARNOSINE ZINC FORMULATIONS AND METHODS OF USE - Various formulations of L-carnosine zinc (L-CAZ), and methods of using and administering such formulations to patients suffering from various diseases, disorders, or conditions are disclosed. In particular, low average particle size L-carnosine zinc is employed in various pharmaceutical compositions, including aqueous matrices and hydrogels. | 2016-04-14 |
20160101049 | METHOD FOR IMPROVING THE PHARMACEUTIC PROPERTIES OF MICROPARTICLES COMPRISING DIKETOPIPERAZINE AND AN ACTIVE AGENT - Methods are provided for drying a particle. Specifically, there is provided a spray-dried diketopiperazine-insulin particle formulation having improved aerodynamic performance and in which the active agent is more stabile and efficiently delivered as compared to that of the lyophilized diketopiperazine-insulin formulation. The dry powders have utility as pharmaceutical formulations for pulmonary delivery. | 2016-04-14 |
20160101050 | OPHTHALMIC NANOEMULSION COMPOSITION CONTAINING CYCLOSPORINE AND METHOD FOR PREPARING SAME - Provided is an ophthalmic nanoemulsion composition and a method for preparing the same which increases the solubility of cyclosporine as an active ingredient and improves the stability of the ophthalmic composition by mixing cyclosporine, a nonaqueous solvent, an emulsifier, and an aqueous solvent, and a method for preventing or treating dry eye syndrome using the same. The ophthalmic nanoemulsion composition is characterized by having an average particle size of 200 nm or less, preferably 100 nm or less, and having a very narrow particle distribution. Therefore, sterilizing filtration is available, stability is improved, and the composition has superior effect in clinical treatment of dry eye syndrome while minimizing foreign body sensation and visual disturbance, and thus the ophthalmic nanoemulsion composition of the present disclosure can be effectively used as an ophthalmic composition. | 2016-04-14 |
20160101051 | Non Surfactant Hydro-Alcoholic Foamable Compositions, Breakable Foams And Their Uses - A substantially surface active agent-free foamable composition which includes short-chain alcohol, water, polymer, fatty alcohol or fatty acid or a combination of fatty alcohol and fatty acid and propellant. A substantially surface active agent-free foamable composition which includes, water, polymer, fatty alcohol or fatty acid and propellant. A method of treatment using a substantially surface active agent-free foamable compositions. | 2016-04-14 |
20160101052 | CONTROLLED RELEASE DOXYCYCLINE - The disclosure provides controlled release compositions comprising tetracyclines and in some embodiments, doxycycline. The controlled release doxycycline compositions of the invention exhibit a superior dissolution profile and provide reduce side effects such as nausea and irritation. | 2016-04-14 |
20160101053 | Reduction Type Coenzyme Q10 Powder, Composition Thereof, And Preparation Method Thereof - The present invention describes a reduction type coenzyme Q10 powder, a composition thereof, and a preparation method thereof. The reduction type coenzyme Q10 powder is obtained by reacting an oxidation type coenzyme Q10 with the presence of a reducing agent, removing an organic solvent and other purities from a reaction solution after the reaction is finished to obtain an oil-soluble reduction type coenzyme Q10 liquid, and then directly performing prill formation with cold wind on an obtained reduction type coenzyme Q10 greasy substance. The obtained reduction type coenzyme Q10 powder has a lower crystallinity, and in a Cu-K[alpha] X-ray diffraction spectrum, has a strong peak at a diffraction angle 2[theta] being 18.9 DEG, and has a very strong absorption peak at a diffraction angle 2[theta] being 22.8 DEG. The reduction type coenzyme Q10 powder obtained in the present invention is in an incompletely crystallized state, has desirable stability and desirable oral bioavailability, and is suitable for use in applications such as dietary supplements, cosmetics or pharmaceuticals. | 2016-04-14 |
20160101054 | SUSTAINED DELIVERY OF DRUGS FROM BIODEGRADABLE POLYMERIC MICROPARTICLES - Biodegradable polymeric microparticle compositions containing one or more active agents, especially those useful for treating or preventing or one or more diseases or disorders of the eye, and methods of making and using thereof, are described. The microsphere compositions release an effective amount of the one or more active agents for a period greater than 14 days in vivo, preferably greater than 60 days in vivo, more preferably up to 73 days in vivo, more preferably greater than 90 days in vivo, even more preferably over 100 days in vivo, and most preferably greater than 107 days in vivo. In a preferred embodiment, the microparticle compositions contain one or more active agents such as AG1478 to induce nerve regeneration, specifically regeneration of the optic nerve useful for managing elevated intraocular pressure (IOP) in the eye. | 2016-04-14 |
20160101055 | METHOD OF PREPARING DRUG AGGLOMERATE - A method of preparing drug agglomerates includes adding a drug powder to a first solvent to form a first solution, adding a second solvent to the first solution to form a second solution. The drug powder undergoes nucleation to form drug agglomerates. The drug agglomerates are isolated from the second solution. | 2016-04-14 |
20160101056 | MUCOADHESIVE DEVICES FOR DELIVERY OF ACTIVE AGENTS - Described herein are systems and methods for transmucosal delivery of active agents. In some embodiments, a system may comprise one or more mucoadhesive devices configured for release of an active agent. | 2016-04-14 |
20160101057 | HOT-MELT EXTRUSION OF MODIFIED RELEASE MULTI-PARTICULATES - The present invention includes compositions and methods of making a modified release pharmaceutical formulation and a method of preparation for the embedding of modified release multi-particulates into a polymeric or wax-like matrix. The modified release multi-particulates comprise an effective amount of a therapeutic compound having a known or desired drug-release profile. Modified release multi-particulates may include a polymeric coat or may be incorporated into particle or core material. The polymer matrix comprises a thermoplastic polymer or lipophilic carrier or a mixture thereof that softens or melts at elevated temperature and allows the distribution of the modified release multi-particulates in the polymer matrix during thermal processing. Formulation compounds and processing conditions are selected in a manner to preserve the controlled release characteristics and/or drug-protective properties of the original modified release multi-particulates. | 2016-04-14 |
20160101058 | BETA-LACTAMASE FORMULATIONS AND USES THEREOF - The present invention provides, in part, formulations comprising a beta-lactamase. Particularly, modified-release formulations comprising a beta-lactamase are provided which release a substantial amount of the beta-lactamase in the intestines. Therapeutic uses of the beta-lactamase formulations are also provided. | 2016-04-14 |
20160101059 | CONTROLLED RELEASE ENTERIC SOFT CAPSULES OF FUMARATE ESTERS - Described herein are pharmaceutical compositions comprising fumarate esters, methods for making the same, and methods for treating subjects in need thereof. In particular, oral pharmaceutical compositions comprising controlled release enteric soft capsules and matrices comprising fumarate esters are described. | 2016-04-14 |
20160101060 | Controlled Release Doxycycline - The disclosure provides controlled release compositions comprising tetracyclines and in some embodiments, doxycycline. The controlled release doxycycline compositions of the invention exhibit a superior dissolution profile and provide reduced side effects such as nausea and irritation. | 2016-04-14 |
20160101061 | PHARMACEUTICAL CARRIER DEVICE SUITABLE FOR DELIVERY OF PHARMACEUTICAL COMPOUNDS TO MUCOSAL SURFACES - The present invention relates to a pharmaceutical delivery device for application of a pharmaceutical to mucosal surfaces. The device comprises an adhesive layer and a non-adhesive backing layer, and the pharmaceutical may be provided in either or both layers. Upon application, the device adheres to the mucosal surface, providing localized drug delivery and protection to the treatment site. The kinetics of erodability are easily adjusted by varying the number of layers and/or the components. | 2016-04-14 |
20160101062 | TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASE AND THROMBOSIS - Provided herein are compositions for the treatment and/or prevention of cardiovascular disease (CVD), and methods of application and use thereof. In particular, the present invention provides treatment and/or prevention of cardiovascular disease with compounds that inhibit the production of TMA in the gut, such as 3,3-dimethyl-1-butanol (DMB) or other compounds represented by Formula I or as shown in FIGS. | 2016-04-14 |
20160101063 | CANNABIDIOL FOR THE PREVENTION AND TREATMENT OF GRAFT-VERSUS-HOST DISEASE - The invention provides methods for preventing, ameliorating and treating the acute and chronic forms of graft-versus-host disease (GVHD) by using Cannabidiol compositions. | 2016-04-14 |
20160101064 | PROCESS FOR PREPARING AN EMULSION OF AN ACTIVE INGREDIENT AND PARTICLES OBTAINED FROM THIS EMULSION - The invention concerns a method for preparing a double emulsion of a fat-soluble and hydrophobic active ingredient, which comprises the following steps:
| 2016-04-14 |
20160101065 | METHOD FOR ENHANCING THE BIOAVAILABILITY OF OSPEMIFENE - This invention relates to a method for enhancing the bioavailability of a therapeutically active compound of the formula (I) | 2016-04-14 |
20160101066 | Fibrin Wafer/Disc as a Biological Carrier for Sustained Delivery of Curcumin - Provided herein is a drug delivery system for curcumin comprising fibrinogen, thrombin and curcumin. | 2016-04-14 |
20160101068 | Anti-Cancer Cycloalkyl Diamines - The invention is directed to a method of treatment of a cancer, in a mammal, the method comprising administering to said mammal in need of such treatment an effective amount of a cell growth inhibitory compound of formula I or a pharmaceutically acceptable salt form thereof. | 2016-04-14 |
20160101069 | METHOD FOR TREATING POST-TRAUMATIC STRESS DISORDER - The present disclosure provides compositions containing ketamine and methods of using those compositions for the treatment of post-traumatic stress disorder. Also provided herein is a pharmaceutical composition that comprises esketamine and a pharmaceutically acceptable carrier, excipient or diluent, for use in treatment of PTSD. In some aspects, the pharmaceutical composition is for intranasal or intravenous administration. In some aspects, the pharmaceutical composition is for use in a method of treating PTSD in a subject. In some aspects, the pharmaceutical composition is for use in a method of treating major depressive disorder in a subject that is co-morbid with the PTSD. | 2016-04-14 |
20160101070 | COMPOSITION COMPRISING ASM INHIBITOR AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING DEGENERATIVE NEUROLOGICAL DISORDERS - The present invention relates to a composition comprising an ASM inhibitor as an active ingredient for preventing or treating degenerative neurological diseases. According to the present invention, when ASM is partially removed in an Alzheimer's disease model mouse, that is when ASM is inhibited therein, such when as an Alzheimer's disease model mouse with a partial removal of ASM is in a parabionic union with an Alzheimer's disease model mouse, or when an Alzheimer's disease model mouse is injected with the serum of an Alzheimer's disease model mouse from which ASM gene has been removed, the deposition of β-amyloid in the brain tissue is inhibited and the ability to learn and remember are improved, and the present invention confirms such superb effects. Accordingly, ASM inhibitor can be effectively used to prevent or treat degenerative neurological diseases. | 2016-04-14 |
20160101071 | COMBINATION CANCER TREATMENT - Described herein is TRAIL receptor targeting therapy in combination with metformin for treatment of cancer in humans. Using TRAIL receptor targeting therapy such as the TRAIL molecule, agonistic human monoclonal antibodies against TRAIL receptors, or peptides targeting TRAIL receptors in combination with metformin for the treatment of all types of cancer allows to obtain an optimum therapeutical effect at any time of the progression of the disease. | 2016-04-14 |
20160101072 | Therapeutic uses of enzyme inhibitors - The invention relates to use of compounds which inhibit VAP-1/SSAO activity for the treatment of muscular dystrophy. The invention also relates to combined preparations comprising compounds which inhibit VAP-1/SSAO activity, and their use for the treatment of muscular dystrophy. | 2016-04-14 |
20160101074 | SULFAMOYLBENZAMIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST HBV INFECTION - The present invention provides sulfamoylbenzamide derivatives, and pharmaceutical compositions thereof. In certain embodiments, the compounds and pharmaceutical compositions of the invention inhibit pregenomic RNA encapsidation. In other embodiments, the compounds and pharmaceutical compositions of the invention are useful for treating Hepatitis B virus (HBV) infection. | 2016-04-14 |
20160101075 | ACAMPROSATE FORMULATIONS, METHODS OF USING THE SAME, AND COMBINATIONS COMPRISING THE SAME - Embodiments disclosed herein generally relate to acamprosate formulations, methods of use of the formulations, to methods of using the formulations optionally in combination with at least one other medication, and to combination products and compositions comprising acamprosate and at least one other medication, such as neuroleptic (antipsychotic) and/or antidepressant drugs. | 2016-04-14 |
20160101076 | Use of Sumoylation Inhibitors for Treating Cancer - The present invention provides methods and reagents for treating cancer cells for therapeutic purposes, by contacting with a sumoylation inhibitor in a dose effective to block sumoylation of TFAP2A. In breast cancer cells the sumoylation inhibitor induces a basal to luminal shift in phenotype. Sumoylation inhibitors also reduce the number of cancer stem cells in a cancer cell population. Inhibition of sumoylation makes cancer cells more responsive to conventional chemotherapeutic therapy and radiation therapy and decreases recurrence or development of metastases. | 2016-04-14 |
20160101077 | Compositions and Methods for Treating Severe Pain - The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions. | 2016-04-14 |
20160101078 | COMPOSITIONS COMPRISING AMINO ACIDS FOR USE IN THE TREATMENT OF STROKE IN PATIENTS WITH DYSPHAGIA - Composition for use in the treatment of stroke, particularly in patients with dysphagia, the composition comprising an active agent, said active agent comprising the amino acids leucine, isoleucine, valine, lysine, threonine and at least one of histidine, phenylalanine, methionine, tryptophan, tyrosine, cystine. The composition further comprises one or more thickener agents in an amount between 10% and 50% by weight, more preferably between 20% and 30% by weight, with respect to the active agent weight. | 2016-04-14 |
20160101079 | PROTECTIVE METALLOTHIONEIN ANALOG COMPOUNDS, THEIR COMPOSITIONS AND USE THEREOF IN THE TREATMENT OF PATHOGENIC DISEASES - Embodiments of the present invention relate generally the use of certain compositions, e.g., compositions comprising a glutathione precursor and a selenium source, in the therapy of viral diseases and/or reducing the incidence of viral diseases. Related embodiments of the present invention relate to treatment and/or reducing the incidence of respiratory ailments caused by respiratory syncytial virus (RSV) or hemorrhagic fever (EHF) caused by Ebola viruses (EBV) or Marburg virus. Yet in other embodiments, the invention relates to reducing metal toxicity in a biological system, which involves contacting the biological system with a composition comprising a glutathione precursor and a selenium source, optionally together with a chelating agent, an antioxidant, a metallothioneine protein or a fragment of metallothioneine. | 2016-04-14 |
20160101080 | ASSAYS, METHODS AND MEANS - A novel class of hydroxylases is described having the amino acid sequence of SEQ ID NO: 2, 4, 6 and 8, and variants and fragments thereof having HIF hydroxylation activity. The polypeptides of the invention have in particular prolyl hydroxylase activity. An assay method monitors the interaction of the IIIF hydroxylase with a substrate. Modulators of IIIF hydroxylase are provided for use in the treatment of a condition associated with increased or decreased HIF levels or activity or for the treatment of a condition where it is desirable to modulate HIF levels or activity. | 2016-04-14 |
20160101081 | COMPOSITIONS AND METHODS FOR ENHANCING MOBILITY OR ACTIVITY OR TREATING FRAILTY - The present invention provides a method for increasing mobility or activity in an animal or treating or preventing frailty in an animal, comprising identifying an animal with decreased mobility or activity or having frailty and administering a composition comprising one or more medium chain triglycerides (MCTs) to the animal in a therapeutically amount effective for increasing mobility or activity in the animal or treating frailty in the animal. Additionally, a food composition can comprise about 15% to about 50% protein, about 5% to about 40% fat, about 5% to about 50% carbohydrate, and about 1% to about 40% of one or more medium chain triglycerides (MCTs); wherein the composition has a moisture content of about 5% to about 20% and the MCTs are present in a therapeutically amount effective for increasing mobility or activity in the animal or treating frailty in the animal. | 2016-04-14 |
20160101082 | PHARMACEUTICAL COMBINATION COMPRISING METFORMIN AND DIHYDROQUERCETIN AND ITS USE FOR THE TREATMENT OF CANCER - Provided is a novel medicament capable of reducing the side effects of metformin or a pharmaceutically acceptable salt thereof and useful as an anti-malignant tumor agent, in which metformin or a pharmaceutically acceptable salt thereof and dihydroquercetin or a pharmaceutically acceptable salt thereof are combined. | 2016-04-14 |
20160101083 | ANTI-PARASITIC METHODS AND COMPOSITIONS UTILIZING DIINDOLYLMETHANE-RELATED INDOLES - The present invention includes methods and compositions for the treatment and prevention of protozoal parasitic infections utilizing Diindolylmethane-related indoles. Additive and synergistic interaction of Diindolylmethane-related indoles with other known anti-parasitic and pro-apoptotic agents is believed to permit more effective therapy and prevention of protozoal parasitic infections. The methods and compositions described provide new treatment of protozoal parasitic diseases of mammals and birds including malaria, leishmaniasis, trypanosomiasis, trichomoniasis, neosporosis and coccidiosis. | 2016-04-14 |
20160101084 | METHODS OF TREATING DEGENERATIVE DISEASES/INJURIES - Invented is a method of treating degenerative diseases/injuries, in a mammal, including a human, in need thereof which comprises the administration of a therapeutically effective amount of a non-peptide TPO receptor agonist to such mammal. | 2016-04-14 |
20160101085 | METHODS OF ADMINISTERING DANTROLENE FOR THE ACUTE TREATMENT OF CARDIAC ARRHYTHMIAS - The present description relates to methods of administering effective amounts of an anti-arrhythmic agent, e.g., dantrolene, azumolene or a pharmaceutically acceptable salt thereof, for the acute treatment of cardiac arrhythmias, e.g., atrial fibrillation, premature ventricular contraction, ventricular tachycardia or ventricular fibrillation, and prevention of subsequent cardiac arrhythmias, wherein the methods effectuate a reduction in morbidity and mortality. | 2016-04-14 |
20160101086 | METHODS OF TREATING MUSCULAR DYSTROPHY - Disclosed herein are methods of improving muscular health, such as enhancing muscle regeneration, maintenance, or repair. In some examples, the method includes administering to the subject an effective amount of an agent capable of increasing activity or expression of estrogen receptor-related gamma (ERRγ), related receptors ERRα or β, or ERR-regulated metabolic and angiogenic genes, thereby enhancing muscle regeneration, maintenance, or repair. In some examples, the methods are utilized to treat a subject with one or more signs or symptoms of muscular dystrophy, such as, but not limited to Duchenne muscular dystrophy. In some examples, the disclosed methods further include selecting a subject in need of enhancing muscle regeneration, maintenance, or repair. | 2016-04-14 |
20160101087 | METHODS FOR DOSING AN ORALLY ACTIVE 1,2,4-OXADIAZOLE FOR NONSENSE MUTATION SUPPRESSION THERAPY - The present invention relates to specific doses of and dosing regimens for using a 1,2,4-oxadiazole benzoic acid compound in treating or preventing diseases associated with nonsense mutations. In particular, the invention relates to specific doses and dosing regimens for the use of 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid in mammals having diseases associated with nonsense mutations. | 2016-04-14 |
20160101088 | COMPOSITION INCLUDING RAPAMYCIN AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING HEARING LOSS - A pharmaceutical or health food includes rapamycin as an active ingredient, the pharmaceutical or health food being applied for prevention, improvement, and treatment of ototoxic hearing loss caused by an aminoglycoside-based antibiotic, sudden sensorineural hearing loss, and noise induced hearing loss. The pharmaceutical or health food is also applied to a pharmaceutical composite preparation of an aminoglycoside-based antibiotic and rapamycin, the pharmaceutical composite preparation reducing a side effect of the aminoglycoside-based antibiotic. | 2016-04-14 |
20160101089 | NOVEL PHARMACEUTICAL SALTS AND POLYMORPHS OF A FACTOR XA INHIBITOR - The present invention provides for salts comprising a compound of Formula I and an acid that has activity against mammalian factor Xa. The present invention is also directed to methods of making the compound of Formula I. | 2016-04-14 |
20160101090 | INHIBITION OF TRK KINASE MEDIATED TUMOR GROWTH AND DISEASE PROGRESSION - It has been shown that Compound 1 unexpectedly and potently inhibits TRK kinases, including all three forms of TRK: NTRK1, NTRK2, and NTRK3. Additionally it has been shown that Compound 1 potently inhibits oncogenic mutated forms of TRK kinases, including fusion proteins. By way of exemplification, Compound 1 potently inhibits the NTRK1 oncogenic fusion protein TPM3/NTRK1 in cellular assays. Compound 1 inhibits TRK kinase mediated tumor growth in vivo in a TPM3/NTRK1 xenograft model. | 2016-04-14 |
20160101091 | ALKYLAMINE DERIVATIVE - A composition containing a compound represented by General Formula (I) below (see the definition in the specification for the symbols in the formula) or a salt thereof has an excellent CaSR agonistic effect and provides a pharmaceutical agent, a CaSR agonistic agent, a prophylactic or therapeutic agent for a disease that can be ameliorated through CaSR activation as well as seasonings and an agent for imparting kokumi. | 2016-04-14 |
20160101092 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF - Provided herein are compounds according to Formula I and pharmaceutically acceptable salts thereof, and compositions comprising the same, for use in various methods, including treating cancers such as colon, ovarian, pancreatic, breast, liver, prostate and hematologic cancers: | 2016-04-14 |
20160101093 | METHODS FOR THE TREATMENT OF PREMATURE EJACULATION - The invention relates to methods of treating premature ejaculation in a patient in need thereof, wherein the methods comprise administering an effective amount of a solution comprising a local anesthetic and/or SSRI, and wherein the solution is injected directly into the penis of the patient. The invention is also related to kits comprising an injection system for physician office/home and/or personal use. | 2016-04-14 |
20160101094 | ASSAYS, METHODS AND MEANS - A novel class of hydroxylases is described having the amino acid sequence of SEQ ID NO: 2, 4, 6 and 8, and variants and fragments thereof having HIF hydroxylation activity. The polypeptides of the invention have in particular prolyl hydroxylase activity. An assay method monitors the interaction of the IIIF hydroxylase with a substrate. Modulators of IIIF hydroxylase are provided for use in the treatment of a condition associated with increased or decreased HIF levels or activity or for the treatment of a condition where it is desirable to modulate HIF levels or activity. | 2016-04-14 |
20160101095 | TREATMENT FOR CEREBRAL PALSY GAIT IMPAIRMENT - A methylphenidate, particularly including dextro-threo-methylphenidate, is administered to a child to treat a gait impairment and a speech impairment secondary to a non degenerative disease or disorder acquired in utero, at birth or in infancy, but later manifested. | 2016-04-14 |
20160101096 | AMINO, AMIDO AND HETEROCYCLIC COMPOUNDS AS MODULATORS OF RAGE ACTIVITY AND USES THEREOF - Amino, amido, and heterocyclic compounds are disclosed. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, diabetes complications, inflammation, and neurodegeneration, obesity, cancer, ischemia/reperfusion injury, cardiovascular disease and other diseases related to RAGE activity. | 2016-04-14 |
20160101097 | Combinations of Glycopyrrolate and Beta2 Adrenoceptor Agonists - A medicament comprising, separately or together (A) glycopyrrolate; and | 2016-04-14 |
20160101098 | SMALL MOLECULE ACTIVATORS OF NRF2 PATHWAY - This disclosure relates to compounds that act as activators of the NRF2/KEAP1/ARE pathway. Specifically, the compounds provided herein can act as high affinity reversible bindings for the NRF2 inhibitor, KEAP1. In some cases, NRF2/KEAP1/ARE pathway activation compounds are capable of repressing expression of inflammatory markers and/or reducing levels of TNFa to provide neuroprotective anti-inflammatory effects in the CNS. Such compounds are useful in the treatment of a variety of diseases including Huntington's disease, Parkinson's disease, Alzheimer's disease, inflammation, and cancer. | 2016-04-14 |
20160101099 | H3 RECEPTOR ANTAGONIST FOR USE IN THE TREATMENT OF ALZHEIMER'S DISEASE - This disclosure relates to methods of using 2-(cyclohexylmethyl)-N-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide in a disease modifying therapy of Alzheimer's disease, other tauopathies and related neurodegenerative diseases. | 2016-04-14 |
20160101100 | TRANSDERMAL DELIVERY SYSTEM - The invention relates to transdermal therapeutic system for the transdermal administration of buprenorphine, comprising a buprenorphine-containing self-adhesive layer structure comprising
| 2016-04-14 |
20160101101 | SUBLINGUAL APOMORPHINE - The invention features sublingual formulations of apomorphine and apomorphine prodrugs, and methods of treating Parkinson's disease, sexual dysfunction, and depressive disorders therewith. | 2016-04-14 |
20160101102 | PIPERAZINE THIAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF TAUOPATHIES SUCH AS ALZHEIMER'S DISEASE - The present invention relates to a compound of formula (IA), wherein G | 2016-04-14 |
20160101103 | METHOD FOR THE PRODUCTION OF A MEDICAMENT CONTAINING TADALAFIL - The invention relates to a method for producing a medicament containing tadalafil. In said method, tadalafil is mixed with suitable adjuvants and is heated to a temperature of about 100° C. to about 200° C., preferably about 150° C. to about 200° C., especially about 200° C. | 2016-04-14 |
20160101104 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS - The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic α7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders. | 2016-04-14 |
20160101105 | HIGH DRUG LOAD TABLET - The present invention pertains to a high drug load tablet comprising as active ingredient Compound I of formula | 2016-04-14 |
20160101106 | METHODS FOR TREATING HCV INFECTION - The present invention provides methods of treating HCV infection in subjects (e.g., mammals), comprising administering to a subject in need thereof an effective amount of a RAF kinase inhibitor or a prodrug thereof. The present invention also provides methods of treating HCV infection, comprising administering to a subject in need thereof an effective amount of a RAF kinase inhibitor conjointly with at least one additional therapeutic agent (e.g., an antiviral agent). | 2016-04-14 |
20160101107 | COMPOUNDS AS MODULATORS OF A MUTANT CFTR PROTEIN AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH CFTR PROTEIN MALFUNCTION - An exemplary embodiment relates to novel protein modulators capable of altering function of the mutant CFTR protein and their use for treating diseases associated with CFTR protein malfunction. The invention provides compositions, pharmaceutical preparations and methods of correcting the cellular alteration of a mutant CFTR protein wherein the CFTR mutation is a mutation ΔF508-CFTR, or another mutation of class II. | 2016-04-14 |
20160101108 | PRINTED DOSAGE FORMS - The present invention relates to oral dosage forms of vitamin(s) and/or dietary mineral(s) or nicotine produced by printing techniques. The present invention also relates to a method of producing an oral dosage form of vitamin(s) and/or dietary mineral(s) or nicotine by printing technique(s). | 2016-04-14 |
20160101109 | METHOD OF TREATING ARTHRITIS - Methods of preventing or treating arthritis is disclosed. | 2016-04-14 |
20160101110 | Novel Formulation of Meloxicam - Unit dosage forms of meloxicam containing either 5 mg or 10 mg of meloxicam that provide effective pain relief and have desirable pharmacokinetic properties are described. The unit dosage forms can provide pain relief when a single unit dose is administered to a patient and useful for treating pain such as osteoarthritis pain at a relatively low systemic exposure to meloxicam. | 2016-04-14 |
20160101111 | COMBINED INHIBITION OF THE VITAMIN D RECEPTOR AND POLY(ADP) RIBOSE POLYMERASE (PARP) IN THE TREATMENT OF CANCER - Methods for treating tumors comprise contacting tumor cells expressing the vitamin D receptor with a vitamin D receptor ligand that inhibits homologous recombination in the tumor cells, and contacting the tumor cells with an amount of a Poly(ADP) Ribose Polymerase 1 (PARP-1) inhibitor. Inhibiting homologous recombination produces a synergistic therapeutic effect between the vitamin D receptor ligand and PARP-1 inhibitor, and may overcome PARP-1 resistance in killing tumor cells. | 2016-04-14 |
20160101112 | PHARMACEUTICAL COMPOSITION COMPRISING N1-CYCLIC AMINE-N5-SUBSTITUTED BIGUANIDE DERIVATIVES AS AN INGREDIENT FOR PREVENTING OR TREATING FIBROSIS - The present invention provides a novel use of N1-cyclic amine-N5-substituted biguanide derivatives for preparing a medicine for preventing or treating fibrosis. The N1-cyclic amine-N5-substituted biguanide derivatives according to the present invention are capable of effectively inhibiting fibrosis by effectively suppressing the EMT. | 2016-04-14 |
20160101113 | AGENT FOR PROMOTING CORNEAL ENDOTHELIAL CELL ADHESION - The invention provides an agent for promoting adhesion of a corneal endothelial cell, containing a Rho kinase inhibitor, as well as a culture medium for a corneal endothelial cell, a solution for preservation of cornea, and a method of producing a corneal endothelial preparation, which includes culturing the corneal endothelial cell using the aforementioned culture medium. | 2016-04-14 |
20160101114 | ARTICLES AND METHODS FOR PREVENTING AND TREATING DERMATOLOGIC ADVERSE EVENTS - The present invention provides articles and methods for preventing or treating dermatologic adverse events. | 2016-04-14 |
20160101116 | ESTROGENIC COMPONENTS FOR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS - The invention relates to the prophylactic and therapeutic applications of certain estrogenic components, such as estetrol in neurological disorders, such as diffuse white matter injury. | 2016-04-14 |
20160101117 | Use of Megestrol Acetate for Improving Heart Function and the Treatment of Heart Insufficiency - The present invention relates to improving the heart function, the survival and/or the treatment of heart insufficiency using megestrol acetate (Megace®; MA) in patients with heart insufficiency and after a myocardial infarction. | 2016-04-14 |
20160101118 | PHARMACEUTICAL COMPOSITIONS FOR INTRAOCULAR ADMINISTRATION AND METHODS FOR FABRICATING THEREOF - Pharmaceutical compositions for intraocular injection are described, the compositions consisting essentially of a therapeutically effective quantity of an anti-bacterial agent (such as moxifloxacin), a therapeutically effective quantity of an anti-inflammatory agent (such as prednisolone), at least one pharmaceutically acceptable excipient and a pharmaceutically acceptable carrier. Methods for fabricating the compositions and using them for intraocular injections are also described. | 2016-04-14 |
20160101119 | Controlled Release Doxycycline - The disclosure provides controlled release compositions comprising tetracyclines and in some embodiments, doxycycline. The controlled release doxycycline compositions of the invention exhibit a superior dissolution profile and provide reduce side effects such as nausea and irritation. | 2016-04-14 |
20160101120 | METHOD FOR PRODUCING A MIXTURE OF NEUTRAL OLIGOSACCHARIDES EXTRACTED FROM FLAXSEED - The method for producing a mixture of neutral oligosaccharides extracted from flaxseed includes oligosaccharides having high molar masses generated by fractionation by ultrafiltration at a cut-off of between 15,000 and 50,000 Da and between 5,000 and 15,000 Da. The mixture of oligosaccharides produced as a result of the implementation of the method, and to the applications of the mixture can be used for skin repair and skin aging control. | 2016-04-14 |
20160101121 | COMPOSITION COMPRISING XANTHOCERAS SORBIFOLIA EXTRACTS, COMPOUNDS ISOLATED FROM SAME, METHODS FOR PREPARING SAME AND USES THEREOF - This invention provides compositions, methods and process of producing extracts from | 2016-04-14 |
20160101122 | COMPOSITIONS AND METHODS FOR TREATING SPINOCEREBELLAR ATAXIA - The present invention provides alleviating a sign or symptom of spinocerebellar ataxia by administering an injection of an aqueous formulation comprising trehalose. | 2016-04-14 |
20160101123 | BETA-MANNOSYLCERAMIDE AND STIMULATION OF NKT CELL ANTI-TUMOR IMMUNITY - β-mannosylceramides or salts or solvates thereof in a pharmaceutically acceptable carrier, for use as a Type I NKT cell agonist in conjunction with a therapeutically effective amount of α-galactosylceramide or a salt or a solvate thereof, and/or at least one or more T-cell co-stimulatory molecules, disclosed. Compositions comprising β-mannosylceramide, as well as methods of treatment of tumors are also provided. | 2016-04-14 |